Suppr超能文献

双示踪剂(68Ga-DOTATOC 和 18F-FDG)-PET/CT 扫描与 G1-G2 无功能性胰腺神经内分泌肿瘤:124 例非转移性切除病例的单中心回顾性评估。

Dual-Tracer (68Ga-DOTATOC and 18F-FDG-)-PET/CT Scan and G1-G2 Nonfunctioning Pancreatic Neuroendocrine Tumors: A Single-Center Retrospective Evaluation of 124 Nonmetastatic Resected Cases.

机构信息

Pancreas Institute, General and Pancreatic Surgery Unit, University of Verona Hospital Trust, Verona, Italy.

Nuclear Medicine Unit, Integrated University Hospital of Verona, Verona, Italy.

出版信息

Neuroendocrinology. 2022;112(2):143-152. doi: 10.1159/000514809. Epub 2021 Jan 28.

Abstract

INTRODUCTION

The combined use of 68gallium (68Ga)-DOTA-peptides and 18fluorine-fluoro-2-deoxyglucose (18F-FDG) positron emission tomography/computed tomography (PET/CT) scans in the workup of pancreatic neuroendocrine tumors (PanNETs) is controversial. This study aimed at assessing both tracers' capability to identify tumors and to assess its association with pathological predictors of recurrence.

METHODS

Prospectively collected, preoperative, dual-tracer PET/CT scan data of G1-G2, nonmetastatic, PanNETs that underwent surgery between January 2013 and October 2019 were retrospectively analyzed.

RESULTS

The final cohort consisted of 124 cases. There was an approximately equal distribution of males and females (50.8%/49.2%) and G1 and G2 tumors (49.2%/50.8%). The disease was detected in 122 (98.4%) and 64 (51.6%) cases by 68Ga-DOTATOC and by 18F-FDG PET/CT scans, respectively, with a combined sensitivity of 99.2%. 18F-FDG-positive examinations found G2 tumors more often than G1 (59.4 vs. 40.6%; p = 0.036), and 18F-FDG-positive PanNETs were larger than negative ones (median tumor size 32 mm, interquartile range [IQR] 21 vs. 26 mm, IQR 20; p = 0.019). The median Ki67 for 18F-FDG-positive and -negative examinations was 3 (IQR 4) and 2 (IQR 4), respectively (p = 0.029). At least 1 pathological predictor of recurrence was present in 74.6% of 18F-FDG-positive cases (vs. 56.7%; p = 0.039), whereas this was not found when dichotomizing the PanNETs by their dimensions (≤/>20 mm). None of the 2 tracers predicted nodal metastasis. The receiver operating characteristic curve analysis showed that 18F-FDG uptake higher than 4.2 had a sensitivity of 49.2% and specificity of 73.3% for differentiating G1 from G2 (AUC = 0.624, p = 0.009).

CONCLUSION

The complementary adoption of 68Ga-DOTATOC and 18F-FDG tracers may be valuable in the diagnostic workup of PanNETs despite not being a game-changer for the management of PanNETs ≤20 mm.

摘要

介绍

在胰腺神经内分泌肿瘤(PanNETs)的检查中,联合使用 68 镓(68Ga)-DOTA-肽和 18 氟-氟代-2-脱氧葡萄糖(18F-FDG)正电子发射断层扫描/计算机断层扫描(PET/CT)扫描存在争议。本研究旨在评估两种示踪剂识别肿瘤的能力,并评估其与肿瘤复发的病理预测因子的相关性。

方法

回顾性分析了 2013 年 1 月至 2019 年 10 月期间接受手术的 G1-G2 级、非转移性 PanNETs 的术前、双示踪剂 PET/CT 扫描的前瞻性采集数据。

结果

最终队列包括 124 例病例。男性和女性的分布大致相等(50.8%/49.2%),G1 和 G2 肿瘤的分布也大致相等(49.2%/50.8%)。分别有 68Ga-DOTATOC 和 18F-FDG PET/CT 扫描检测到 122(98.4%)和 64(51.6%)例疾病,联合敏感性为 99.2%。18F-FDG 阳性检查发现 G2 肿瘤比 G1 肿瘤更常见(59.4%比 40.6%;p=0.036),且 18F-FDG 阳性 PanNETs 比阴性 PanNETs 更大(中位肿瘤大小 32mm,IQR 21 vs. 26mm,IQR 20;p=0.019)。18F-FDG 阳性和阴性检查的 Ki67 中位数分别为 3(IQR 4)和 2(IQR 4)(p=0.029)。18F-FDG 阳性病例中至少存在 1 种复发的病理预测因子的比例为 74.6%(vs. 56.7%;p=0.039),而根据肿瘤大小(≤/>20mm)对 PanNETs 进行二分法时,并未发现这种情况。两种示踪剂均未预测淋巴结转移。受试者工作特征曲线分析显示,18F-FDG 摄取量高于 4.2 时,用于区分 G1 和 G2 的敏感性为 49.2%,特异性为 73.3%(AUC=0.624,p=0.009)。

结论

尽管对于≤20mm 的 PanNETs 管理来说,联合使用 68Ga-DOTATOC 和 18F-FDG 示踪剂并不是一个改变游戏规则的方法,但在 PanNETs 的诊断评估中采用这两种示踪剂可能具有价值。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验